Department of Clinical Pharmacology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Laboratory of Clinical Neurophysiology, AHEPA University Hospital, Aristotle University of Thessaloniki, 54006, Thessaloniki, Greece.
CNS Neurol Disord Drug Targets. 2020;19(3):220-226. doi: 10.2174/1871527319666200518100716.
Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique that is being actively explored as a potential therapeutic modality in various neuropsychiatric disorders, such as depression, neuropathic pain, epilepsy, multiple sclerosis, and neurodegenerative disorders, including the Parkinson's and Alzheimer's disease. The Food and Drug Administration (FDA) approved rTMS for the treatment of major depression, migraine-associated headaches, and Obsessive Compulsive Disorder (OCD). The fact that a significant proportion of patients suffering from these disorders fail to respond to current pharmacological interventions indicates the need for alternative therapies like rTMS.
The objective was to find and summarize all studies combining the use of rTMS and pharmacological interference in vitro, in order to facilitate future studies.
The results of studies combining the use of rTMS with pharmacological interference in vitro were focused on. The PubMed database was searched using the terms "rTMS", "repetitive", "transcranial", "magnetic", "stimulation", "in vitro", "in vivo", "cell cultures" untilMarch 2019 and 7 eligible studies were found.
Overall results show a synergistic effect of rTMS and pharmacotherapy in vitro with additive effectiveness, better prognosis, and superior potential management.
The limited amount of knowledge denotes the need for additional in vitro studies on the combination of rTMS and pharmacotherapy, which could be extended to in vivo studies and ultimately help design clinical trials so as to improve the therapeutic management of patients with a wide array of neuropsychiatric disorders.
重复经颅磁刺激（rTMS）是一种非侵入性脑刺激技术，目前正在积极探索作为各种神经精神疾病的潜在治疗方法，如抑郁症、神经性疼痛、癫痫、多发性硬化症和神经退行性疾病，包括帕金森病和阿尔茨海默病。美国食品和药物管理局（FDA）批准 rTMS 用于治疗重度抑郁症、偏头痛相关头痛和强迫症（OCD）。事实上，相当一部分患有这些疾病的患者对目前的药物干预没有反应，这表明需要替代疗法，如 rTMS。
目的是找到并总结所有将 rTMS 与体外药理学干扰相结合的研究，以便为未来的研究提供便利。
关注将 rTMS 与体外药理学干扰相结合的研究结果。使用“rTMS”、“重复”、“经颅”、“磁”、“刺激”、“体外”、“体内”、“细胞培养”等术语在 PubMed 数据库中进行搜索，直到 2019 年 3 月，共找到 7 项符合条件的研究。
总体结果表明，rTMS 和体外药物治疗具有协同作用，具有附加效果、更好的预后和更高的潜在管理效果。
由于知识有限，需要对 rTMS 和药物治疗的联合进行更多的体外研究，这些研究可以扩展到体内研究，并最终有助于设计临床试验，从而改善各种神经精神疾病患者的治疗管理。
